Journal of Pharmacovigilance

New pattern clinical study of adverse drug reaction to ART may lead to chase drug discovery in antiretroviral drug towards zero adverse drug reaction

10^th Pharmacovigilance Congress

September 20-21, 2017 Charlotte, USA

Rahul Hajare

Rajgad Dnyanpeethâ??s College of Pharmacy, India

Scientific Tracks Abstracts: J Pharmacovigil

Abstract:

ART drug is widely used Anti-HIV agents. Of these, molecular recognition in their molecular nucleus likes diarylpyrimidine, benzoxazinone, heterocyclic most present in ART. Apart from these, some hetero atom along with some special core group have been reported. They are effective and not very costly, though there are also possibilities of ART adverse reactions common with use of ART. Cross reactivity between for example Etravirine and Rilpivirine, earlier reported may exceed 30%. Common adverse drug reaction for highly protein bound ART, includes hypersensitivity reactions were characterized by rash, fever and sometimes organ involvement including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and eosinophilia. indices were included. Adverse drug reactions caused by drugs belonging to no longer their therapeutic effect or alter their adverse events profile. Hence, this study has undertaken to promote health care setting, so researcher movement initially began inside hospitals and clinics. This study adverse drug reaction has setting drug discovery in HIV technology in collaboration with microbiologist, physicians, pharmacist, nurse practitioners and other healthcare professionals then there are adverse reactions could have been prevented or may lead to zero adverse reaction ART. Also, this study has shown of critical analyzing the clinical profile of these reactions, grading them and trying to figure out ways to deliver actual drug discovery to prevent these adverse reactions. Reports were messaged to see clinical pharmacist stating explicitly that the clinical pharmacist cares for patients in all health care settings emphasizes two points: that clinical pharmacist provides care to their patients and that this practice can occur in any practice setting. The study aims to assess the role of clinical pharmacist in identification and reporting of adverse drug reactions in antiretroviral therapy and consideration of new pattern clinical study.

Biography :

Rahul Hajare has completed his PhD from Vinayaka Missions University. He is a Post-Doctoral Fellow at Indian Council of Medical Research New Delhi. His primary area of research was to study and model of binding energy complexes determination, characterization and examination of selected new series of resistance mutation and noted changes in interaction between target compound and HIV-1 mutant. His notable works include identification and characterization of small molecules and development of model speed drug discovery and development of a series of novel, scaffold on a molecular recognition of HIV-1 inhibitors synthesized using a parallel synthesis unit processes technology. He joined the R & D, Aarti Drugs Limited Mumbai; initial work established the modernization of Analytical Laboratory and R&D laboratory. The role also involves generation of funds through intra- and extra-mural projects, capacity building through infra-structure development and training and overall leadership for the academic industry. He has close linkage with National AIDS Research Institute, ICMR, ACS, AAPS, Biomaterial Society, OMICS International, Fragment-based Drug Discovery, Autism Researchers Link, Allied academies, BIT’s. He has more than 60 papers in reputed journals and has been serving as an Editorial Board Member of repute.